Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING Trial: VX-210 in Acute Cervical SCI
NCT02669849Phase 3Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Nov 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
A Phase 3 trial of cethrin in Spinal cord injury (SCI), sponsored by Vertex Pharmaceuticals. Started Jul 2016; status: terminated.
02
Drugs
cethrin
03
Conditions
Spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT02669849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02669849.